Literature DB >> 12699390

Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.

Andre Rosowsky1, Ronald A Forsch, Sherry F Queener.   

Abstract

As part of an ongoing effort to discover novel small-molecule antifolates combining the enzyme-binding species selectivity of trimethoprim (TMP) with the potency of piritrexim (PTX), 10 previously unreported 2,4-diamino-5-(2'-methoxy-5'-substituted)benzylpyrimidines (2-11) containing a carboxyl group at the distal end of the 5'-substituent were synthesized and tested as inhibitors of dihydrofolate reductase (DHFR) from Pneumocystis carinii (Pc), Toxoplasma gondii (Tg), and Mycobacterium avium (Ma), three of the opportunistic pathogens frequently responsible for life-threatening illness in people with impaired immune systems as a result of HIV infection or immunosuppressive chemotherapy. The selectivity index of DHFR inhibition was evaluated by comparing the potency of each compound against the parasite enzymes with its potency against rat liver DHFR. 2,4-Diamino-5-[5'-(5-carboxy-1-pentynyl)-2'-methoxybenzyl]pyrimidine (3) inhibited Pc DHFR with a selectivity index of 79 and was 430 times more potent than TMP. 2,4-Diamino-5-[5'-(4-carboxy-1-butynyl)-2'-methoxybenzyl]pyrimidine (2), with one less carbon than 3 in the side chain, had a selectivity index of 910 against Ma DHFR and was 43 times more potent than TMP. 2,4-Diamino-5-[5'-(5-carboxypentyl)-2'-methoxybenzyl]pyrimidine (6) had a selectivity index of 490 against Tg DHFR and was 320 times more potent than TMP. 2,4-Diamino-5-[5'-(6-carboxy-1-hexynyl)-2'-methoxybenzyl]pyrimidine (4), with one more carbon than 3, was less potent against all three of the parasite enzymes than either 3 or 6 and also had a lower selectivity index than 3 against the Pc enzyme. However, 4 was the only member of the series with a selectivity index of >300 against both Tg and Ma DHFR. Given that PTX is at least 10 times more potent against rat DHFR than against P. carinii or T. gondii DHFR and that the selectivity index of several of the compounds matches or exceeds that of TMP as well as PTX, our results suggest that it may be possible to develop clinically useful nonclassical antifolates that are both potent and selective against the major opportunistic pathogens of AIDS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699390     DOI: 10.1021/jm020466n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Structural analysis of Pneumocystis carinii dihydrofolate reductase complexed with NADPH and 2,4-diamino-6-[2-(5-carboxypent-1-yn-1-yl)-5-methoxybenzyl]-5-methylpyrido[2,3-d]pyrimidine.

Authors:  Vivian Cody; Jim Pace; Elizabeth Stewart
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-03-28

2.  Structural analysis of Pneumocystis carinii and human DHFR complexes with NADPH and a series of five potent 6-[5'-(ω-carboxyalkoxy)benzyl]pyrido[2,3-d]pyrimidine derivatives.

Authors:  Vivian Cody; Jim Pace
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-12-16

3.  Structure-activity relationships of Bacillus cereus and Bacillus anthracis dihydrofolate reductase: toward the identification of new potent drug leads.

Authors:  Tammy M Joska; Amy C Anderson
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

4.  In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.

Authors:  Esther W Barrow; Jürg Dreier; Stefan Reinelt; Philip C Bourne; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

5.  Selective antifolates for chemically labeling proteins in mammalian cells.

Authors:  Laura E Pedró Rosa; D Rajasekhar Reddy; Sherry F Queener; Lawrence W Miller
Journal:  Chembiochem       Date:  2009-06-15       Impact factor: 3.164

6.  Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity.

Authors:  Christina R Bourne; Richard A Bunce; Philip C Bourne; K Darrell Berlin; Esther W Barrow; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

7.  Towards new antifolates targeting eukaryotic opportunistic infections.

Authors:  Jieying Liu; David B Bolstad; Erin S D Bolstad; Dennis L Wright; Amy C Anderson
Journal:  Eukaryot Cell       Date:  2009-01-23

8.  Correlations of inhibitor kinetics for Pneumocystis jirovecii and human dihydrofolate reductase with structural data for human active site mutant enzyme complexes.

Authors:  Vivian Cody; Jim Pace; Jennifer Makin; Jennifer Piraino; Sherry F Queener; Andre Rosowsky
Journal:  Biochemistry       Date:  2009-03-03       Impact factor: 3.162

9.  Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase.

Authors:  Jennifer M Beierlein; Kathleen M Frey; David B Bolstad; Phillip M Pelphrey; Tammy M Joska; Adrienne E Smith; Nigel D Priestley; Dennis L Wright; Amy C Anderson
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

Review 10.  Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors.

Authors:  Agnieszka Wróbel; Karolina Arciszewska; Dawid Maliszewski; Danuta Drozdowska
Journal:  J Antibiot (Tokyo)       Date:  2019-10-02       Impact factor: 2.649

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.